Thursday, May 8, 2014
Publication and contact
Platelet derived growth factor receptor B (PDGFRB;
Studies in mice and human
samples suggest inhibiting PDGFRB could help prevent pancreatic cancer
metastasis. In mice injected with metastasis-prone pancreatic cancer cells,
shRNA knockdown or pharmacological inhibition of Pdgfrb with crenolanib
decreased metastatic spread compared with no alteration or inhibition. In
human pancreatic ductal adenocarcinoma samples, elevated levels PDGFRB
correlated with poor disease-free survival and decreased time to relapse.
Next steps could include evaluating pharmacological PDGFRB inhibitors in
additional pancreatic cancer models.
Novartis AG markets Gleevec,
tyrosine kinase inhibitor, to treat chronic myelogenous
leukemia (CML), acute lymphoblastic leukemia (ALL) and gastrointestinal
stromal tumors (GISTs).
Pharmaceuticals LLC's crenolanib is in Phase II testing to
treat acute myelogenous leukemia (AML) and Phase I to treat brain cancer.
Published online May 8, 2014
Patent and licensing status
Weissmueller, S. et al.
Cell; published online April 10, 2014;
Contact: Scott W. Lowe, Memorial Sloan Kettering Cancer
New York, N.Y.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]